ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 580,03
-0,69%
Dow Jones
40 954,48
1,85%
DAX
18 518,03
-0,44%
Brent Oil
83,32
-1,21%
Bitcoin
64 720,71
-0,20%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Intellia Therapeutics Inc (NTLA)

  7. Intellia Therapeutics Inc (NTLA) Actualités

NTLA

Intellia Therapeutics (NTLA)

Intellia Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:NTLA
DateHeureSourceTitreSymboleSociété
01/11/201712h12Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:NTLAIntellia Therapeutics Inc
01/11/201712h00GlobeNewswire Inc.Intellia Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:NTLAIntellia Therapeutics Inc
31/10/201713h03Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:NTLAIntellia Therapeutics Inc
31/10/201712h42Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NTLAIntellia Therapeutics Inc
31/10/201712h30GlobeNewswire Inc.Intellia Therapeutics Announces Third Quarter 2017 Financial ResultsNASDAQ:NTLAIntellia Therapeutics Inc
30/10/201721h35GlobeNewswire Inc.Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2017 EarningsNASDAQ:NTLAIntellia Therapeutics Inc
03/10/201722h35GlobeNewswire Inc.Intellia Therapeutics to Present at October Healthcare Investor ConferencesNASDAQ:NTLAIntellia Therapeutics Inc
26/09/201713h30GlobeNewswire Inc.Intellia Therapeutics Demonstrates Sustained and Durable Genome Editing with CRISPR/Cas9 in One-Year Animal StudyNASDAQ:NTLAIntellia Therapeutics Inc
14/09/201700h30Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NTLAIntellia Therapeutics Inc
07/09/201723h00GlobeNewswire Inc.Intellia Therapeutics to Present at Upcoming September Investor Healthcare ConferencesNASDAQ:NTLAIntellia Therapeutics Inc
01/08/201713h30GlobeNewswire Inc. Intellia Therapeutics Announces Second Quarter 2017 Financial ResultsNASDAQ:NTLAIntellia Therapeutics Inc
25/07/201723h00GlobeNewswire Inc.CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appellate Brief Seeking Reversal of...NASDAQ:NTLAIntellia Therapeutics Inc
25/07/201722h47Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:NTLAIntellia Therapeutics Inc
25/07/201700h30GlobeNewswire Inc.Intellia Therapeutics Names Moncef Slaoui, Ph.D. and Frank Verwiel, M.D. to Its Board of Directors and Establishes a Science ...NASDAQ:NTLAIntellia Therapeutics Inc
19/06/201713h30GlobeNewswire Inc.Intellia Therapeutics Announces Patent for CRISPR/Cas Genome Editing in ChinaNASDAQ:NTLAIntellia Therapeutics Inc
19/06/201712h03Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:NTLAIntellia Therapeutics Inc
06/06/201713h15GlobeNewswire Inc.Intellia Therapeutics and San Raffaele University and Research Hospital to Combine CRISPR/Cas9 Genome Editing with Enhanced C...NASDAQ:NTLAIntellia Therapeutics Inc
05/06/201723h09Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:NTLAIntellia Therapeutics Inc
05/06/201723h05Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:NTLAIntellia Therapeutics Inc
13/05/201714h40GlobeNewswire Inc.Intellia Therapeutics Announces Progress with CRISPR/Cas9 at the American Society of Gene & Cell Therapy Annual MeetingNASDAQ:NTLAIntellia Therapeutics Inc
02/05/201713h30GlobeNewswire Inc.Intellia Therapeutics Announces First Quarter 2017 Financial ResultsNASDAQ:NTLAIntellia Therapeutics Inc
26/04/201713h30GlobeNewswire Inc.Intellia Therapeutics and CRISPR Therapeutics Announce U.S. Patent Covering CRISPR/Cas9 Ribonucleoprotein ComplexesNASDAQ:NTLAIntellia Therapeutics Inc
18/04/201723h14Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:NTLAIntellia Therapeutics Inc
13/04/201713h30GlobeNewswire Inc.CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appeal of CRISPR/Cas9 U.S. Patent B...NASDAQ:NTLAIntellia Therapeutics Inc
11/04/201713h30GlobeNewswire Inc.Intellia Therapeutics Announces European Patent Office’s Decision to Grant CRISPR/Cas9 Genome Editing Technology PatentNASDAQ:NTLAIntellia Therapeutics Inc
14/03/201722h32Edgar (US Regulatory)Annual Report (10-k)NASDAQ:NTLAIntellia Therapeutics Inc
14/03/201712h15GlobeNewswire Inc.Intellia Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial ResultsNASDAQ:NTLAIntellia Therapeutics Inc
08/03/201713h30GlobeNewswire Inc.Intellia Therapeutics Demonstrates Pioneering CRISPR/Cas9 Genome Editing Efficiency Data Using Lipid Nanoparticle Delivery T...NASDAQ:NTLAIntellia Therapeutics Inc
01/03/201713h10GlobeNewswire Inc.Intellia Therapeutics to Present at March Investor Healthcare ConferencesNASDAQ:NTLAIntellia Therapeutics Inc
16/02/201700h41GlobeNewswire Inc.Intellia Therapeutics to Hold Conference Call to Address Patent Interference ProceedingsNASDAQ:NTLAIntellia Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:NTLA

Dernières Valeurs Consultées

EU
ML
Michelin
NASDAQ
GOOGL
Alphabet
FTSE
UKX
FTSE 100
EU
CS
Axa
COIN
ETHUSD
Ethereum
EU
BEL20
Bel 20
NYSE
NKE
Nike
EU
CAP
Capgemini
EU
ORA
Orange
EU
AF
Air FranceKLM
NYSE
KO
Coca Cola
EU
PX4
SBF 120
NASDAQ
AMZN
Amazon.com
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés